Abstract:Background Transcutaneous vaccines have received wide attention due to their easy-to-use, needle-free, noninvasive delivery. However, the novel barrier function of stratum corneum hinders the transport of antigen and adjuvant in transcutaneous immunization. Novel nanoscale delivery systems employing, for example, liposomes and nanoparticles, have been widely investigated to overcome the penetration barrier of stratum corneum for effective transcutaneous immunization. Objective The objective of this study was to prepare two types of flexible liposomes and determine their efficacies for the transcutaneous delivery of antigen and the subsequent immune response induced in vivo. Methods Ovalbumin (OVA) liposome-based transcutaneous vaccines were prepared using reverse-phase evaporation and film-dispersion methods. Particle sizes and antigen encapsulating efficiency were then evaluated. After application to bare mouse skin, topical sites were examined for the presence of fluorescence-labeled liposome. The efficacy of the transcutaneously delivered OVA-loaded flexible liposome in activating the immune responses was investigated by detecting serum immunoglobulin G levels. The influence of an adjuvant, imiquimod, in the transcutaneous immunization was also tested. Results Two flexible liposomes with well-encapsulated OVA were successfully prepared by film-dispersion or reverse-phase evaporation methods. The sizes of the prepared flexible liposomes ranged from 200 to 400 nm. In vivo, the fluorescence-labeled liposome was detected in hair-follicle ducts, indicating that the flexible liposome can penetrate the skin barrier through the hair follicles. Upon transcutaneous administration, the OVA-encapsulated flexible liposome elicited a strong immune response similar to that of positive control (ie, OVA solution administrated by subcutaneous injection with Al(OH)3 as an adjuvant). Co-administration of imiquimod with the OVA-loaded liposome expressed a significant enhancement on the transcutaneous immune responses. Conclusion Results of this study highlight the nanoscale formulation, flexible liposome, as a promising carrier for the transcutaneous delivery of antigen proteins. Imiquimod was shown to be an effective adjuvant as a transcutaneous immunization enhancer with the potential for transcutaneous vaccine development.

Augmentation of Antigen-Specific Immune Responses Using DNA-fusogenic Liposome Vaccine.

Non-Methylated Cpg Motif Packaged into Fusogenic Liposomes Enhance Antigen-Specific Immunity in Mice

Increasing a robust antigen-specific cytotoxic T lymphocyte response by FMDV DNA vaccination with IL-9 expressing construct.

Potentiation of antigen‐specific, Th1 immune responses by multiple DNA vaccination with an ovalbumin/interferon‐γ hybrid construct

Enhanced in vivo gene expression mediated by listeriolysin O incorporated anionic LPDII: Its utility in cytotoxic T lymphocyte-inducing DNA vaccine.

Enhanced Immunogenicity of Foot and Mouth Disease DNA Vaccine Delivered by PLGA Nanoparticles Combined with Cytokine Adjuvants

Fusogenic Liposome Can Be Used As an Effective Vaccine Carrier for Peptide Vaccination to Induce Cytotoxic T Lymphocyte (CTL) Response

Mechanism on antigen delivery under mucosal vaccination using cell-penetrating peptides immobilized at multiple points on polymeric platforms

Induction of potent antitumor immunity by intradermal DNA injection using a novel needle‐free pyro‐drive jet injector

Intranasal Vaccination With Recombinant Antigen-FLIPr Fusion Protein Alone Induces Long-Lasting Systemic Antibody Responses and Broad T Cell Responses

DNA Vaccine-Encapsulated Virus-Like Particles Derived from an Orally Transmissible Virus Stimulate Mucosal and Systemic Immune Responses by Oral Administration

Effective Transcutaneous Immunization by Antigen-Loaded Flexible Liposome in Vivo

Enhanced Protective Efficacy and Reduced Viral Load of Foot-and-mouth Disease DNA Vaccine with Co-Stimulatory Molecules As the Molecular Adjuvants.

Vaccine Efficacy of Fusogenic Liposomes Containing Tumor Cell-Lysate Against Murine B16BL6 Melanoma.

Humoral and cellular immunity to an encoded protein induced by direct DNA injection.

Progress for Improving the Immune Response of DNA Vaccine

Strong Immune Responses Induced by Direct Local Injections of Modified Mrna-Lipid Nanocomplexes.

Engineering of in Vivo Immune Responses to DNA Immunization Via Codelivery of Costimulatory Molecule Genes.

704/DNA vaccines leverage cytoplasmic DNA stimulation to promote anti-HIV neutralizing antibody production in mice and strong immune response against alpha-fetoprotein in non-human primates

A Novel Liposome-Polymer Hybrid Nanoparticles Delivering a Multi-Epitope Self-Replication DNA Vaccine and Its Preliminary Immune Evaluation in Experimental Animals

Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity